Market Access News | pharmaphorum

News

FDA rejects Novo Nordisk’s weekly basal insulin

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US.

News

FTC said to be planning legal action against PBMs

The Federal Trade Commission in the US is planning to sue the owners of the three largest pharmacy benefits managers (PBMs) for anti-competitive behaviour, on the heels of its damning repor

News

NICE backs monthly eczema drug from Almirall

NHS England has been cleared to allow prescribing of Almirall’s Ebglyss for some people with atopic dermatitis, giving them the option of a therapy that only needs to be injected once a mon

News

After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis

After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema

News

FTC report finds PBM power has “dire consequences”

A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.

News

Roche will relaunch AMD implant Susvimo after update

Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to manufa

FDA rejects Novo Nordisk’s weekly basal insulin

FTC said to be planning legal action against PBMs

NICE backs monthly eczema drug from Almirall

After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis

FTC report finds PBM power has “dire consequences”

Roche will relaunch AMD implant Susvimo after update

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

News

Editor's Picks